When working in the field of life-threatening infectious diseases, you are racing against rapidly evolving pathogens.
Of the dozens of potential assets within the fungerp family of triterpenoid antifungals, we have narrowed the focus to the most promising of the antifungal compounds to investigate powerful systemic therapeutic options. The development of the second-generation treatments has begun.
Some of the key advantages of triterpenoid are the broad spectrum of activity, safety and high tissue penetration compared to other antifungals. SCY-247 is a second generation triterpenoid showing significant promise. The collective attributes of broad spectrum of activity, favorable tolerability and high tissue penetration make SCY-247 an attractive development candidate for the treatment and prevention of difficult to treat and emerging fungal infections like C. auris, and those in anatomic areas not adequately reached by other antifungals.